About the BHMA
The
British Herbal Medicine Association (BHMA) was founded in 1964 to advance the
science and practice of herbal medicine in the United Kingdom and to ensure its
continued statutory recognition at a time when all medicines were becoming
subject to greater regulatory control. It is worth noting that the BHMA was
established on the principle that herbal remedies are medicines
under UK law, and should be produced to medicine requirements for quality,
safety and efficacy,
rather than to lesser requirements for "dietary supplements" or
healthfoods.
Following
the Medicines Act 1968 the legislative requirements for herbal medicines
increased substantially. During the 1980s, as part of the EC Review of
Medicines, all UK medicine manufacturers were required to complete a thorough
technical appraisal of their products and to provide evidence on quality, safety
and efficacy to the Medicines Control Agency on behalf of the Department of
Health. Around 600 herbal products emerged from this rigorous review with full
medicine product licences and with their claims for efficacy accepted by the
government. (They can be identified on the product pack by a "PL"
number). In addition there are a larger number of herb products that are
supplied as herbal medicines exempt from licensing under the terms of the
Medicines Act, provided that they contain herbs only, have no brand names and
that no medicinal claims are made for the products. In addition to many herbal
products available directly to the public, herbal practitioners also supply
their medicines under these terms.
In
1998 the BHMA developed a Code of
Practice for the production of herbal medicines exempt from licensing that
all its members have signed up to. In effect this means that BHMA members are
committed to producing all their herbal medicines to the same pharmaceutical
standards of quality that are required for licensed medicines. In the absence of
legally binding quality standards for the production of herbal medicines exempt
from licensing, the BHMA Code is the main assurance to the public that herbal
products can be safe and efficacious. The Medicines Control Agency has welcomed
the BHMA Code as an important contribution to its work in regulating herbal
medicines.
From
its foundation the BHMA has provided important scientific information to health
professions, the herbal industry and to the public. Notably from the 1970's it
has produced the British Herbal
Pharmacopoeia (latest edition 1996), recognised in the UK and in many
countries around the world as the leading reference on the scientific definition
of herbal medicines to complement official drug pharmacopoeias. To complement
the BHP the BHMA has also published the British
Herbal Compendium of therapeutic information on plants listed in the
pharmacopoeia, and has substantial new publications in progress.
The
BHMA is the UK representative of (and provides the Secretariat for) the European
Scientific Cooperative on Phytotherapy (ESCOP) the body that has become
recognised by the European Medicines Agency as providing the leading scientific
resources on the therapeutic use of herbal medicinal products in the European
Union. Harmonised European medicine dossiers based on submissions by ESCOP will
soon be published by the European Medicines Agency.
Members
of the BHMA include companies involved in the manufacture or supply of herbal
medicines, herbal practitioners, academics, pharmacists, students of
phytotherapy and others. The BHMA
has supported these members with advice and comments on legislation and
labelling from the beginning. However the
BHMA is not able to provide individual clinical advice to members of the public and
refers enquiries to members of the main professional associations of herbal
practitioners. In the UK tradition the leading professional groups, now with
University degree-level education, are the College of Practitioners of
Phytotherapy (CPP) and the National Institute of Medical Herbalists (NIMH).
Practitioner members of these bodies can be identified, in Yellow Pages and
other listings of herbal practitioners, by the letters MCPP, FCPP, MNIMH or
FNIMH after their names.
Objectives of the Association
To defend the right of the public to choose herbal remedies and to be able to obtain them freely.
To encourage wider knowledge and recognition of the value of herbal medicine.
To advance the science and practice of herbal medicine by modern techniques.
To promote high standards of quality and safety in herbal remedies.
To foster research in phytotherapy, exploring the vast potential of medicinal plants.
Since its formation in 1965 the BHMA Scientific Committee has played an important role in the Association's activities. With many distinguished contributors, the Committee has a long record of achievement in developing monographs on plant drugs and in providing technical information to BHMA members and public bodies.
From the first monographs published in 1971 the Pharmacopoeia was gradually extended and updated culminating, after 16 years of dedicated study and practical work, in a unified edition, the British Herbal Pharmacopoeia 1983, with specifications and therapeutic information on 232 plant drugs.
In recent years the Committee has pursued a long term programme towards full revision of the BHP, as a source of specifications, particularly for plant drugs not featured in the BP, and also the preparation of a new companion publication, British Herbal Compendium, combining therapeutics with much needed data on other aspects of herbal medicines. The outcome is two separate but closely related books for the 1990's. Click here to see more detail about BHMA publications.
To support its work on publications the committee has compiled an extensive database of scientific papers and endeavours to keep up-to-date with scientific and regulatory progress on plant drugs of interest. Contact is maintained with the Medicines Control Agency and the BP commission and, when appropriate, the Committee provides information and comment on regulatory or pharmacopoeial matters.
Committee members also represent the BHMA as delegates to the Scientific Committee of ESCOP and provide substantial assistance to its work on proposals for European monographs on the medicinal uses of plant drugs. Involvement in ESCOP meetings and symposia ensures close liaison with representatives of academia and industry from many European countries.